Measuring the costs and benefits of pharmaceutical expenditures

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 5, 2002, Pages 467-475

  Crown, William H ^a   Ling, Davina ^a   Berndt, Ernst ^a  

^a MEDSTAT GROUP   (United States)

Author keywords

Cost of disease accounting; Decomposition; Expenditure; Healthcare price index; Pharmaceutical expenditures; Pharmacoeconomics

Indexed keywords

ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; GASTROINTESTINAL AGENT; HORMONE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ASTHMA; CLINICAL RESEARCH; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEPRESSION; DRUG COST; HEALTH CARE COST; HEALTH CARE QUALITY; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; TREATMENT OUTCOME;

EID: 0036796427     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.5.467     Document Type: Review

References (23)

1. Berndt ER. The US pharmaceutical industry: why major growth in times of cost containment? Health Affairs 20 (2), 100-114 (2001).
2. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N. Engl. J. Med 331, 650-655 (1994).
3. Soumerai SB, Lipton HL. Computer-based drug utilization review-risk, benefit, or boondoggle? N. Engl. J. Med. 15 (24), 1641-1645 (1995).
4. Horn SD et al. Intended and unintended consequences of HMO cost containment strategies: results from the managed care outcomes project. Am. J. Managed Care (March), 253-264 (1996).
5. Lichtenberg F. Do (more and better) drugs keep people out of hospitals. Am. Econ. Rev. (May), 384-388 (1996).
6. Lichtenberg FR. Are the benefits of drug, worth their cost? evidence from the 1996 MEPS. Health Affairs 20(5), 241-251 (1996).
7. Newhouse J. Medical care price indices: problems and opportunities. Academia Economic Papers 29 (1), 1-65 (2001).
8. Danzon P, Pauly M. Insurance and new technology: from hospitals to drugstore. Health Affairs 20(5), 86-100 (2001).
9. Triplett J. Accounting for Health Care: Integrating Price Index and Cost-Effectiveness Research. In: Measuring the Prices of Medical Treatments. Triplett J (Ed.), Brookings Institution Press, Washington, DC, USA, 220-250 (1999).
10. Schultze CL, Mackie C (Eds). At What Price? Conceptualizing and Measuring Cost-of-Living and Price Indexes. National Academy Press, Washington, DC, USA (2002).
11. Scitovsky AA. Changes in the costs of treatment of selected illnesses, 1951-65. Am. Econ. Rev. 57(5), 1182-1195 (1967).
12. Scitovsky AA. Changes in the costs of treatment of selected illnesses, 1971-1981. Med. Care 23(12), 1345-1357 (1981).
13. Dubois RW, Chawla AJ, Neulusan CA, Smith MA, Wade S. Explaining drug spending trends: does perception match reality? Health Affairs 19(2), 231-239 (2000).
14. Merlis M. Explaining the growth in prescription drug spending: a review of recent studies. Prepared for the Department of Health and Human Services, Conference on Pharmaceutical Pricing Practices, Utilization and Costs. Washington, DC, USA (2000).
15. Crown W, Treglia M. Specification issues in Econometric Models of Pharmacoeconomic Outcomes: An Application to Depression Treatment. Annual Meeting of the American Economics Association. Boston, MA, USA (2000).
16. Garber A. Advances in Cost-Effectiveness Analysis of Health Interventions. Handbook of Health Economics 181-221 (2000).
17. Ozminkowski R, Wang S, Marder W, Azzolini J, Schutt D. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. PharmacoEconomics 18(3), 253-264 (2000).
18. Ozminkowski R, Wang S, Marder W, Azzolini J. Short-run association between medical care expenditures and adherence to clinical practice guideline-based measures for diabetes. Value in Health 3(s1), 29-38 (2000).
19. Berndt ER, Bir A, Busch SH, Frank RG, Normand S-IT. The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexes. J. Health Econ. (In Press).
20. Crown WH, Treglia M, Meneades L, White A. Long-term costs of treatment for depression: Impact of drug selection and guideline adherence. Value in Health 4(4), 295-307 (2001).
21. Crown WH. Antidepressant selection and economic outcome: a review of methods and studies from clinical practice. Br. J. Psychiatry 179(Suppl. 42), s18-s22 (2001).
22. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342(25), 1887-1892 (2000).
23. Benson K. Hartz AJ. A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med. 342(25), 1878-1886 (2000).